Advanced Filters
noise

post-menopausal-osteoporosis Clinical Trials

A listing of post-menopausal-osteoporosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 20 clinical trials

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women

The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.

- 100 years of age Female Phase N/A

Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

Denosumab of Intas is biosimilar denosumab candidate under development by Intas Pharmaceutical Limited (Biopharma Division). Denosumab of Intas is already approved by Indian drug licensing authority- Drug Controller General (India) for marketing in Indian population since 2018.As per regulatory requirement, a comparative clinical study to establish Pharmacokinetic, Pharmacodynamic and Immunogenicity …

55 - 90 years of age Female Phase 3

A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

This is a phase 3 Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis

55 - 85 years of age Female Phase 3

Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis

Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality. Given potential side effects, hormone replacement therapy is no longer recommended for menopausal women with risk of becoming osteoporotic. The very significant decrease in the …

50 - 65 years of age Female Phase N/A

Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis

To investigate the efficacy and safety of eldecalcitol in postmenopausal women with low bone mineral density (BMD) or mild osteoporosis through a randomized, open-label, parallel controlled trial with calcitriol as the control.

50 - 100 years of age Female Phase 4
L Lise Laclautre

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.

50 - 100 years of age Female Phase N/A

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)

The aims of ZOLARMAB2 are fourfold. First, the investigators want to investigate if multiple infusions of zoledronate can prevent the rebound activation of bone turnover and the subsequent bone loss in patients previously treated with denosumab and if there is difference between infusing zoledronate at fixed time-points after the last …

40 - 100 years of age Female Phase 4
M Mackenzie Jordan

Mechanisms of Anabolic Osteoporosis Therapy

The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.

45 - 100 years of age Female Phase N/A

MAGnesium Effect With ANtiosteoporotic Drugs

Randomized pilot clinical trial to demonstrate superiority of bisphosphonate-magnesium combination over bisphosphonates alone in postmenopausal osteoporosis in slowing bone remodeling as assessed by C-terminal telopeptide of bone collagen type 1 (CTX) dosage.

50 - 100 years of age Female Phase 2
W William Friedman

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women will be enrolled over a period of 18 months. The co-primary outcomes will be group differences in bone mineral density (BMD) of …

45 - 100 years of age Female Phase 4

Rewrite in simple language using AI